LATEST TWEETS - CURATED BY HASH FINANCE

Form 8-K: On May 7, 2021, BeiGene, announced that its PARP inhibitor pamiparib has received conditional approval fr… https://t.co/zkDrVuFIDb
BeiGene Reports First Quarter 2021 Financial Results $BGNE https://t.co/DMSMyadU0H
BeiGene's pamiparib OK'd in China for ovarian cancer $BGNE https://t.co/SBUBRtg0DZ
CSIMarket.com (CSIMarket) 17 hours ago
$BGNE #StockMarket #BeigeneLtd issued financial time frame ending Mar 31 2021 Results on https://t.co/savSNTKlN1: D… https://t.co/8X6LGNmqEl
SEC.report (EdgarInsider) 18 hours ago
Filing for 8-K [Press/News Current Report] has been made with the SEC: $BGNE #BeiGene, Ltd. https://t.co/cDJDzMcRlv
Fintel (fintel_io) 1 day ago
$BGNE / BeiGene files form 8-K - Financial Statements and Exhibits, Other Events - 8-K https://t.co/87zQOLJVaV
BeiGene, Ltd current quarter revenue growth YoY of 68.10% ranked 329 out of 5451 companies in our database.… https://t.co/mI040kICUS
BeiGene Rises 4% on Q1 Revenue, Earnings Beat - $BGNE #Stocks - via @CapitalWatchCom https://t.co/zo6M8eyX3L
BeiGene receives conditional China NMPA approval for pamiparib $BGNE
$BGNE China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer https://t.co/SEj0YT7AIC
$BGNE China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer https://t.co/0Da2fUVuyd
$BGNE China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer https://t.co/YM5V7YBgUY
STCK.PRO (StckPro) 1 day ago
$BGNE NEW ARTICLE : China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovar… https://t.co/PcN40s2JcP
BeiGene : China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer… https://t.co/GjxwUUwXO2
China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer $BGNE https://t.co/cg1ecpTCKE
$BGNE China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer… https://t.co/1zKSzdnGgR
$BGNE: BeiGene beats by $3.27, product revenue up 103.6% https://t.co/KYtueGez24
BeiGene Q1 EPS $0.69 Up From $(4.70) YoY, Sales $106.10M Up From $52.06M YoY Related Tickers: $BGNE Read more at: https://t.co/ihlMzJSaQM
$BGNE revs double to $106M q over q. China bellwether sitting on nearly $5B in cash. what do you think they'll do w… https://t.co/zJ6vBvnAkY
New Form 8-K [Press/News Current Report] entry filed by $BGNE #BeiGene, Ltd. #BeiGene, Ltd https://t.co/9KAHRBJ93A
Filing for 10-Q [Quarterly Report] has been made with the SEC: $BGNE #BeiGene, Ltd. #BeiGene, Ltd https://t.co/NnWeZGiEKQ
BeiGene reports Q1 EPS 69c vs. ($4.70) a year ago. $BGNE
$BGNE reported earnings of $0.69, consensus was ($3.35) via @eWhispers #epsbeat https://t.co/E8nRq5jorD
Retweet selected by the https://t.co/11ojAZA3Wf team | Q1 2020 Earnings Forecast for Beigene Ltd (NASDAQ:BGNE) Iss… https://t.co/Q7cRdP3LXY
BGNE (BeiGene, Ltd.) 🚨 #Insider #stock alert! 💰 #Sale on 2021-05-03 - $BGNE 🇺🇸: Wu Xiaobin (President, COO & GM Chi… https://t.co/VSfsonqnWt